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Cervical dystonia is characterized by involuntary abnormal movements and postures of the 
head and neck. We often experience long-term remission of cervical dystonia after several 
botulinum toxin treatments 1). To confirm whether botulinum toxin acts on the central 
level2-5) as well as neuromuscular junctions, we study the changes of brain metabolism in a 
cervical dystonia patient with spinocerebellar ataxia type 1 (SCA1) before and after 
botulinum toxin A (BTX-A) therapy using 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET)1).  
A 33-year-old man was hospitalized with severe fixed retrocollis, very mild 
cerebellar ataxia and pyramidal tract sign. Sensory trick, stereotype, and task specificity 
were observed. Brain MRI showed mild atrophy in the cerebellum and pons. Genetic 
analysis revealed expanded 49 CAG repeats in the SCA1 gene. An initial FDG-PET study 
was performed one month after the initial BTX-A treatment. His retrocollis exhibited 
dramatic and sustained improvement after several BTX-A treatments and was still 
improved 9 months after the last BTX-A treatment. A second FDG-PET study was then 
performed. The time difference between the first and second scans was 20 months. The 
types and doses of drugs were the same in the two FDG-PET studies.  
We compared the FDG PET findings of this patient before or after BTX-A therapy 
to those of 18 age-matched normal controls. Two-sample t-tests were used for comparisons 
between the normal controls and the patient before and after BTX-A therapy using SPM5 
software. The statistical threshold was set at family-wise error (FWE) p<0.001. The study 
protocol was approved by the Ethical Committee of Tohoku University Graduate School of 
141 
 
Medicine and a written informed consent was obtained from each subject after a complete 
description of the study. In the initial FDG-PET study, this patient showed hypermetabolism 
in the bilateral putamen and primary sensorimotor cortex compared to the 18 normal 
subjects. After the BTX-A therapy, most of the hypermetabolism in the bilateral putamen 
and primary sensorimotor cortex disappeared in this patient compared to in the normal 
group. 
Because the frequency of dystonia in SCA1 patients is about 0 to 15%6-8), cervical 
dystonia may be a presenting symptom in some patients with SCA1. Cervical dystonia 
showed a significant hypermetabolism in the lentiform nucleus9) or the putamen10) 
compared to normal controls using FDG PET. The cervical dystonia in this patient could be 
dramatically improved by the depression of hypermetabolism in the bilateral putamen and 
primary sensorimotor cortex after several BTX-A treatments. Therefore, the overactivities 
of bilateral putamen and primary sensorimotor cortex may be one of the most important 
factors for the pathogenesis of cervical dystonia with SCA1. 
Cervical dystonia in this patient was improved in the long-term after several BTX-A 
treatments. BTX-A may act on the central nervous system (CNS) through afferent pathways 
from the injected site2). This patient is the first report to demonstrate that hypermetabolism 
in the bilateral putamen and primary sensorimotor cortex in cervical dystonia returns to 
normal after BTX-A therapy. We suggest that BTX-A has some effects on the CNS level to 





1) Kikuchi A., Takeda A., Sugeno N., Miura E., Kato K., Hasegawa T., Baba T., Konno M., Oshima 
R., Watanuki S., Hiraoka K., Tashiro M. and Aoki M., Intern. Med. 55 (2016) 1919.  
2) Giladi N., J. Neurol. Sci. 152 (1997) 132. 
3) Kanovsky P., Streitova H., Dufek J., Znojil V., Daniel P. and Rektor I., Mov. Disord. 13 (1998) 
108. 
4) Ceballos-Baumann A.O., Sheean G., Passingham R.E., Marsden C.D. and Brooks D.J., Brain. 
120 (1997) 571. 
5) Etgen T., Muhlau M., Gaser C. and Sander D., J. Neurol. Neurosurg. Psychiatry. 77 (2006) 1017. 
6) Lee W.Y., Jin D.K., Oh M.R., Lee J.E., Song S.M., Lee E.A., Kim G.M., Chung J.S. and Lee 
K.H., Arch. Neurol. 60 (2003) 858. 
7) Pareyson D., Gellera C., Castellotti B., Antonelli A., Riggio M.C., Mazzucchelli F., Girotti F., 
Pietrini V., Mariotti C. and Di Donato S., J. Neurol. 246 (1999) 389. 
8) Sasaki H., Fukazawa T., Yanagihara T., Hamada T., Shima K., Matsumoto A., Hashimoto K., Ito 
N., Wakisaka A. and Tashiro K., Acta. Neurol. Scand. 93 (1996) 64. 
9) Magyar-Lehmann S., Antonini A., Roelcke U., Maguire R.P., Missimer J., Meyer M. and 
Leenders K.L., Mov. Disord. 12 (1997) 704. 
10) Galardi G., Perani D., Grassi F., Bressi S., Amadio S., Antoni M., Comi G.C., Canal N. and Fazio 
F., Acta. Neurol. Scand. 94 (1996) 172. 
 
